sygnaturediscovery.com Report : Visit Site

Technical data of the sygnaturediscovery.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host sygnaturediscovery.com. Currently, hosted in United States and its service provider is Merit Network Inc. .

the related websites

pharmaron.co.uk talktofrank.com terrapinn.com addicted.org medindia.net insightcrime.org hse.gov.uk dailymail.co.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx/1.13.12 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

-- project login +44 115 941 5401 search drug discovery integrated drug discovery target validation hit identification hit-to-lead lead optimisation fragment-based drug discovery structure-based drug discovery projects chemistry medicinal chemistry synthetic chemistry analytical chemistry high throughput chemistry bioscience assay development screening cellular assays biochemical assays biophysical assays biomarker discovery primary tissues in vivo pharmacology computational sciences and informatics target analysis virtual screening structure-based drug design ligand-based drug design library design admet prediction informatics dmpk and physical sciences physicochemical profiling in vitro adme in vivo pharmacokinetics pk and bioanalysis metabolite identification and biotransformation ivive and human pk predictions dmpk consultancy discovery toxicology hepatotoxicity mechanistic toxicity non-glp exploratory toxicology therapeutic areas oncology and immuno-oncology inflammation and immunology respiratory neuroscience anti-infectives orphan disease diabetes news and events news events (re)thinking drug discovery publications case studies posters presentations technical notes journal papers careers vacancies why work for sygnature training and development about who we are meet our team company history contact show results for sygnature news drug discovery therapeutic areas events vacancies the route to a new drug isn't always clear... next ...but those familiar with the terrain will find a way... next ...to push through on the journey to success. next 01 02 03 explore what we do sygnature discovery - enabling success dmpk and physical sciences discover chemistry discover bioscience discover integrated drug discovery sygnature provides experienced drug discovery teams, across multiple discipline's in order to maximise the chances of rapidly reaching your next drug candidate. discover computational sciences and informatics discover discovery toxicology discover in vivo pharmacology discover who we are sygnature discovery provides experienced, innovative, multi-disciplinary drug discovery teams to support client projects across a wide range of therapeutic areas and target classes. about us therapeutic areas oncology and immuno-oncology we have successfully delivered more than 16 pre-clinical oncology projects, utilising our integrated drug discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer. from initial screening and profiling through to clinically relevant biomarkers, our dmpk and bioscience group can provide full support for your discovery projects. discover diabetes diabetes is a metabolic disorder that is an increasingly prevalent disease worldwide. we have established assays to support the investigation of diabetic therapies including relevant functional assays. we also have access to tissue and blood from in vivo diabetic models through strategic collaborations. discover orphan disease sygnature’s team of scientists have a strong track record of adding value to client projects in the field of rare and orphan diseases. sygnature’s advanced intellectual input and established relationships with providers of diseased tissue allows rapid progression of projects in this challenging therapeutic area. discover anti-infectives sygnature have a history of enabling discovery success in the field of anti-infectives. our medicinal chemistry and computational chemistry teams have worked in close collaboration with many clients to design potent and efficacious compounds, resulting in the delivery of two preclinical candidates. our bioscience team can provide cytopathic effect and viability screening assays to assess compounds designed to inhibit virus attachment, entry or replication in human host cells. discover neuroscience our scientists have a well-developed understanding of the challenges associated with the design and optimisation of compounds that target the central nervous system (cns). our experience is both broad, reaching across a number of neurodegenerative diseases (such as alzheimer’s, parkinson’s and amyotrophic lateral sclerosis) and neuropathic pain, and deep-rooted, with members of our senior team having 10+ years in cns drug research. discover respiratory we have an excellent track record of success in the field of respiratory diseases using our extensive in-house expertise, accelerating 5 compounds to the clinic and a further 4 into preclinical development for our clients. our collaborative approach to drug discovery and our established network of kols in the field have been invaluable to the progression of our clients’ projects discover inflammation and immunology our scientists have a rich heritage in this therapeutic area and provide significant experience in developing in vitro assays utilising peripheral blood mononuclear cells (pbmcs), t lymphocytes (e.g. cd4+/cd8+), leukocytes, and phagocytes, amongst others, that assess various inflammation and immunological biomarkers, processes, and endpoints. discover latest news view all 1st august 2019 hidden chemistry in flowers shown to kill… 29th may 2019 sygnature discovery and renasci strengthen in vivo… 28th may 2019 sygnature discovery test-drives spr-m 2nd may 2019 sygnature discovery continues its support to the… get in touch for more details on how we can provide innovative support to your project please use this contact form. cta form if you are human, leave this field blank. name * email * message recaptcha the information you supply will be processed in accordance with the general data protection regulation (eu) 2016/679. for further details about how sygnature discovery collects, uses and stores personal data, please refer to our website privacy notice available here. submit sygnature discovery limited, biocity, pennyfoot street, nottingham ng1 1gr, united kingdom company no. 05210563 vat no. 180703717 t: +44 115 941 5401 e: [email protected] e: [email protected] drug discovery therapeutic areas about contact news website privacy notice cookie policy 1st august 2019 hidden chemistry in flowers shown to kill cancer cells 29th may 2019 sygnature discovery and renasci strengthen in vivo pharmacology service-offering get in touch for more details on how we can provide innovative support to your project please use this contact form. newsletter signup if you are human, leave this field blank. name * email address * message * the information you supply will be processed in accordance with the general data protection regulation (eu) 2016/679. for further details about how sygnature discovery collects, uses and stores personal data, please refer to our website privacy notice available here. * i agree recaptcha submit copyright © 2019 sygnature discovery web design and development by fifteen --

URL analysis for sygnaturediscovery.com

https://www.sygnaturediscovery.com/drug-discovery/bioscience/screening/
https://www.sygnaturediscovery.com/drug-discovery/in-vivo-assays/
https://www.sygnaturediscovery.com/drug-discovery/integrated-drug-discovery/
https://www.sygnaturediscovery.com/publications/journal-papers/
https://www.sygnaturediscovery.com
https://www.sygnaturediscovery.com/drug-discovery/computational-sciences-informatics/structure-based-drug-design/
https://www.sygnaturediscovery.com/drug-discovery/bioscience/cellular-assays/
https://www.sygnaturediscovery.com/drug-discovery/computational-sciences-informatics/target-analysis/
https://www.sygnaturediscovery.com/drug-discovery/integrated-drug-discovery/hit-identification/
https://www.sygnaturediscovery.com/drug-discovery/computational-sciences-informatics/ligand-based-drug-design/
https://www.sygnaturediscovery.com/drug-discovery/bioscience/biomarker-discovery/
https://www.sygnaturediscovery.com/about/meet-our-team/
https://www.sygnaturediscovery.com/drug-discovery/bioscience/biophysical-assays/
https://www.sygnaturediscovery.com/drug-discovery/dmpk-and-physical-sciences/pk-bioanalysis-metabolite-id/
https://www.sygnaturediscovery.com/drug-discovery/dmpk-and-physical-sciences/
fifteendesign.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Whois Server Version 2.0

Domain names in the .com and .net domains can now be registered
with many different competing registrars. Go to http://www.internic.net
for detailed information.

Domain Name: SYGNATUREDISCOVERY.COM
Registrar: TUCOWS DOMAINS INC.
Sponsoring Registrar IANA ID: 69
Whois Server: whois.tucows.com
Referral URL: http://www.tucowsdomains.com
Name Server: NS1.LIVEDNS.CO.UK
Name Server: NS2.LIVEDNS.CO.UK
Name Server: NS3.LIVEDNS.CO.UK
Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Updated Date: 02-jun-2017
Creation Date: 01-jul-2011
Expiration Date: 01-jul-2026

>>> Last update of whois database: Tue, 11 Jul 2017 02:07:18 GMT <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR TUCOWS DOMAINS INC.

  REFERRER http://www.tucowsdomains.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =sygnaturediscovery.com

  PORT 43

  SERVER whois.tucows.com

  ARGS sygnaturediscovery.com

  PORT 43

  TYPE domain

DOMAIN

  NAME sygnaturediscovery.com

NSERVER

  NS1.LIVEDNS.CO.UK 213.171.192.250

  NS2.LIVEDNS.CO.UK 213.171.193.250

  NS3.LIVEDNS.CO.UK 213.171.192.254

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

  CHANGED 2017-06-02

  CREATED 2011-07-01

  EXPIRES 2026-07-01

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .